Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study ; volume:23 ; number:1 ; day:25 ; month:7 ; year:2024 ; pages:1-11 ; date:7.2024
BMC cancer ; 23, Heft 1 (25.7.2024), 1-11, 7.2024
- Urheber
-
Cicin, Irfan
Plimack, Elizabeth R.
Gurney, Howard
Leibowitz, Raya
Alekseev, Boris Y.
Parnis, Francis X.
Peer, Avivit
Necchi, Andrea
Bellmunt, Joaquim
Nishiyama, Hiroyuki
Clark, Jason
Munteanu, Mihaela
Kataria, Ritesh
Jia, Calvin
Powles, Thomas
Sternberg, Cora N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11213-6
- URN
-
urn:nbn:de:101:1-2410102120204.698339137552
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cicin, Irfan
- Plimack, Elizabeth R.
- Gurney, Howard
- Leibowitz, Raya
- Alekseev, Boris Y.
- Parnis, Francis X.
- Peer, Avivit
- Necchi, Andrea
- Bellmunt, Joaquim
- Nishiyama, Hiroyuki
- Clark, Jason
- Munteanu, Mihaela
- Kataria, Ritesh
- Jia, Calvin
- Powles, Thomas
- Sternberg, Cora N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Pembrolizumab
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab for all
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Pembrolizumab
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab for all
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
Pembrolizumab
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab for all
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial